Epizyme logo
Epizyme EPZM

Quarterly report 2022-Q2
added 08-09-2022

report update icon

Epizyme Net Debt 2011-2025 | EPZM

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Epizyme

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
122 M 52.1 M 125 M -86.6 M -227 M -77.2 M -207 M -190 M -124 M -98 M -33.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
125 M -227 M -67.5 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-107 M $ 4.72 0.96 % $ 783 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
-22 M $ 3.32 -1.19 % $ 257 M usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
469 M $ 25.26 -2.47 % $ 1.22 B usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
-119 M - -15.15 % $ 60.3 M britainBritain
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-195 M $ 209.93 -0.11 % $ 5 B danmarkDanmark
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 1.31 -1.88 % $ 7.14 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-34.7 M $ 3.4 -0.71 % $ 8.18 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
9.86 B $ 89.77 -0.57 % $ 96.9 B britainBritain
Anika Therapeutics Anika Therapeutics
ANIK
-46 M $ 9.59 1.05 % $ 141 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-29.7 M - -5.38 % $ 6.06 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-2.44 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
-34.7 M - -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
-60.5 M - -7.31 % $ 87 M usaUSA
Biogen Biogen
BIIB
4.01 B $ 174.05 0.9 % $ 25.3 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
-19.9 M $ 2.33 2.08 % $ 14.6 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
-25.4 M - -6.81 % $ 3.04 B usaUSA
Baudax Bio Baudax Bio
BXRX
1.86 M - 0.59 % $ 63 K usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.13 K - -52.27 % $ 4.45 M usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
-1.92 M $ 12.26 -5.4 % $ 505 M usaUSA
BioNTech SE BioNTech SE
BNTX
-973 M $ 94.78 -1.28 % $ 27.2 B germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
ChromaDex Corporation ChromaDex Corporation
CDXC
-26.5 M - -0.88 % $ 598 M usaUSA
Axon Enterprise Axon Enterprise
AXON
-404 M $ 570.12 -1.88 % $ 43.2 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-3.5 M $ 0.28 -2.76 % $ 609 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
-33.1 M $ 14.66 -4.25 % $ 965 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
-40.8 M - - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-22.3 M - -16.75 % $ 25.8 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
293 M - -7.23 % $ 13 M usaUSA
BioVie BioVie
BIVI
-17.2 M $ 1.47 -2.55 % $ 2.17 M usaUSA
Cortexyme Cortexyme
CRTX
-68.6 M - -1.05 % $ 67.1 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
-24.5 M $ 27.54 -1.43 % $ 1.77 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
-9.01 M $ 3.61 -4.5 % $ 44.1 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
-57.6 M - - $ 2.18 B usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
455 M $ 11.3 -1.22 % $ 731 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
-9.94 M - -5.68 % $ 8.28 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
645 K - - $ 40.5 M usaUSA
Cerus Corporation Cerus Corporation
CERS
-6.33 M $ 2.15 -0.23 % $ 397 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA